ProQR Therapeutics (PRQR) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free PRQR Stock Alerts $1.98 -0.02 (-1.00%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineProQR Therapeutics (NASDAQ:PRQR) Cut to "Sell" at StockNews.commarketbeat.com - May 11 at 12:16 AMProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development Potentialmarkets.businessinsider.com - May 10 at 4:34 PMBuy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial Footingmarkets.businessinsider.com - May 10 at 4:34 PMProQR Therapeutics' (PRQR) "Buy" Rating Reaffirmed at Chardan Capitalmarketbeat.com - May 10 at 12:21 PMProQR Therapeutics N.V.: ProQR Announces First Quarter 2024 Operating and Financial Resultsfinanznachrichten.de - May 9 at 3:25 PMProQR Announces First Quarter 2024 Operating and Financial Resultsglobenewswire.com - May 9 at 7:00 AMBuy Recommendation on ProQR’s Innovative RNA Editing Platform and Promising Clinical Prospectsmarkets.businessinsider.com - May 8 at 9:36 PMProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer(TM) RNA Editing Program Targeting NTCP for Cholestatic Diseasesstockhouse.com - May 8 at 11:11 AMProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseasesfinance.yahoo.com - May 8 at 11:11 AMProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual Meetingstockhouse.com - April 24 at 10:59 AMProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024globenewswire.com - April 23 at 7:00 AMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingfinance.yahoo.com - April 22 at 4:41 PMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingglobenewswire.com - April 22 at 4:31 PMProQR retains key patent for RNA editing technologyuk.investing.com - April 21 at 10:34 PMProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP Portfoliostockhouse.com - April 20 at 8:50 PMProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolioglobenewswire.com - April 19 at 7:00 AMCitigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00marketbeat.com - April 18 at 12:13 PMProQR Therapeutics N.V. (PRQR)finance.yahoo.com - April 8 at 10:59 AMProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Analystsmarketbeat.com - March 29 at 2:14 AMProQR Therapeutics (NASDAQ:PRQR) Given "Buy" Rating at HC Wainwrightmarketbeat.com - March 18 at 4:33 PMChardan Capital Boosts ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.50marketbeat.com - March 18 at 4:33 PMProQR Therapeutics (NASDAQ:PRQR) Short Interest Updatemarketbeat.com - March 15 at 8:19 PMBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic Disordersmarkets.businessinsider.com - March 14 at 7:10 PMBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing Platformmarkets.businessinsider.com - March 14 at 9:09 AMProQR Therapeutics Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 14 at 9:09 AMProQR Announces Year End 2023 Operating and Financial Resultsglobenewswire.com - March 13 at 7:00 AMProQR Therapeutics (NASDAQ:PRQR) Upgraded by StockNews.com to Buymarketbeat.com - March 11 at 11:15 PMPRQR Mar 2024 2.500 callfinance.yahoo.com - February 18 at 1:10 PMProQR Therapeutics N.V.wsj.com - February 16 at 8:41 AMProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editingfinance.yahoo.com - February 15 at 8:39 AMProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokeragesmarketbeat.com - February 8 at 1:34 AMStockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Holdmarketbeat.com - February 2 at 1:19 AM4 Biotech Stocks With Massive Buy Potentialstocknews.com - January 30 at 12:06 PMStockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to Buymarketbeat.com - January 25 at 1:25 AMProQR Therapeutics N.V.: ProQR Highlights New Platform Data from Presentation on Axiomer RNA Editing Technology at Deaminet 2024finanznachrichten.de - January 19 at 10:54 AMProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024finance.yahoo.com - January 19 at 10:54 AMWhile institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the mostfinance.yahoo.com - January 15 at 10:48 AMProQR Therapeutics (NASDAQ:PRQR) Sees Large Decrease in Short Interestmarketbeat.com - January 13 at 7:21 PMBuy Rating Affirmed for ProQR on Strategic Partnership and Promising Axiomer RNA Editing Platformmarkets.businessinsider.com - January 6 at 9:56 AMProQR Therapeutics N.V.: ProQR and Rett Syndrome Research Trust Join Forces with Axiomer RNA Editing Collaborationfinanznachrichten.de - January 5 at 2:10 PMProQR Therapeutics Stock (NASDAQ:PRQR) Dividends: History, Yield and Datesbenzinga.com - January 5 at 9:09 AMProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaborationfinance.yahoo.com - January 5 at 9:09 AMProQR Therapeutics (NASDAQ:PRQR) Stock Rating Upgraded by StockNews.commarketbeat.com - January 4 at 10:13 PMIs ProQR (PRQR) Stock a Solid Choice Right Now?finance.yahoo.com - December 28 at 3:51 PMProQR’s Strategic Divestiture and Strong Financial Outlook Justify Buy Ratingmarkets.businessinsider.com - December 9 at 7:34 AMProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assetsfinance.yahoo.com - December 8 at 10:21 AMProQR Therapeutics NV PRQRmorningstar.com - November 21 at 10:48 PMPositive Report for ProQR (PRQR) from Chardan Capitalmarkets.businessinsider.com - November 9 at 10:51 AMBuy Rating for ProQR Therapeutics: Robust RNA-Editing Patent Portfolio, Promising Preclinical Candidates, and Strong Financial Positionmarkets.businessinsider.com - November 9 at 10:51 AMChardan Capital Upgrades ProQR Therapeutics N.V (PRQR)msn.com - November 8 at 11:17 PM Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Charles Payne Demystifies Options (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. PRQR Media Mentions By Week PRQR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRQR News Sentiment▼0.670.58▲Average Medical News Sentiment PRQR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRQR Articles This Week▼121▲PRQR Articles Average Week Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Gossamer Bio News Today Skye Bioscience News Today Seres Therapeutics News Today Prelude Therapeutics News Today Capricor Therapeutics News Today Incannex Healthcare News Today CervoMed News Today Greenwich LifeSciences News Today I-Mab News Today scPharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRQR) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeObama’s Forever Term [exposed]Porter & CompanyCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
